このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

前立腺がんの治療を受けた男性における尿失禁に対する表面電気刺激の第 II 相試験

2026年11月7日 更新者:National Cancer Institute (NCI)

Background:

Men who are treated for prostate cancer often develop urinary leakage (incontinence). An experimental device that uses electrical impulses to stimulate pelvic floor muscles and surrounding tissues may help.

Objective:

To see if the Elidah device can reduce urinary incontinence after prostate treatment.

Eligibility:

Men aged 18 years and older who have had moderate urinary incontinence for at least 6 months after treatment for prostate cancer.

Design:

Participants will be in the study for about 9 weeks. They will be screened. They will have a physical exam with urine tests.

The Elidah device consists of a Controller and a GelPad. The Controller sets the strength of electrical impulses. The GelPad is placed against the skin under the pelvis.

Participants will be given an Elidah device and taught how to use it at home.

They will use the device once a day for 20 minutes at a time; they will do this 5 days a week for 6 weeks.

Participants will complete a daily log. They will record the strength of electrical impulses (0-35); the number of incontinence episodes; the type of incontinence episode; and the number of used pads.

Participants will do a pad weight test. For 3 days before and 3 days after using the Elidah device, they will collect all of their used pads for each 24-hour period into a sealed plastic bag. They will also collect a second set of bags that contain dry versions of each product used.

Participants will have clinic visits after using the device for 3 weeks and after finishing the 6 weeks of treatment.

Participants will complete 15-minute questionnaires.

調査の概要

詳細な説明

Background:

  • Urinary incontinence is a common side effect of prostate cancer therapy that can negatively impact the quality of life.
  • Standard treatment includes an initial course of pelvic floor muscle exercises followed by surgical therapy if urinary incontinence persists.
  • Although pelvic floor muscle exercises can be successful in reducing urinary incontinence, compliance with exercises is poor.
  • The Elitone (registered trademark) device was recently cleared by the Food and Drug Administration (FDA) for use in women with stress urinary incontinence. This device provides a surface electrical muscle stimulation device designed to contract the pelvic floor muscles and has been shown to reduce incontinence in women using the product.
  • Recently, the electrode component (GelPad) of the device has been adapted for use in men by the manufacturing company, Elidah. The male version of the device is named the Elidah device.

Objective:

-To describe the efficacy of the Elidah device on male urinary incontinence

Eligibility:

  • Participants must be male.

  • Participants must have a history of urinary incontinence for at least 6 months after prostate cancer treatment.

  • Participants must have at least one of the following types of urinary incontinence:

    • stress urinary incontinence, defined as involuntary loss of urine on effort or physical exertion (e.g., sporting activities), or on sneezing or coughing;
    • urge urinary incontinence, defined as a compelling need to urinate, due to pain or an unpleasant sensation, that is difficult to defer.

Design:

  • This is a phase II trial testing the efficacy of the Elidah device in people treated for prostate cancer with stress and/or urge urinary incontinence.
  • Prior to treatment, participants will undergo baseline assessments including 24-hour pad weight testing and questionnaires relating to incontinence and quality of life.
  • Participants will self-administer the Elidah device treatment for 20 minutes per day, 5 days per week during a 6-week period in the at-home environment. Participants will maintain a Daily Log to record usage of the Elidah device, urinary leaks, and use of pads during each week of treatment.
  • Following 6 weeks of therapy, participants will undergo re-evaluation of symptoms and urinary incontinence via questionnaires and testing with the 24-hour pad weight test.

研究の種類

介入

入学 (推定)

41

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Maryland
      • Bethesda、Maryland、アメリカ、20892
        • 募集
        • National Institutes of Health Clinical Center
        • コンタクト:
          • National Cancer Institute Referral Office
          • 電話番号:888-624-1937

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~120年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

男

説明

  • INCLUSION CRITERIA:

  • Participants must be male.

  • Participants must have a history of urinary incontinence for at least 6 months after local prostate cancer treatment.

  • Participants must have at least one of the following types of urinary incontinence:

    • stress urinary incontinence, defined as involuntary loss of urine on effort or physical exertion (e.g., sporting activities) or on sneezing or coughing
    • urge urinary incontinence, defined as a compelling need to urinate, due to pain or an unpleasant sensation, that is difficult to defer.
  • Participants must have moderate urinary incontinence defined as use of 1-4 pads per day by self-report at screening.

  • Participants must be able to read and write in English.

  • Age >= 18 years.

  • Eastern Cooperative Oncology Group (ECOG) performance status <= 2.

  • Ability to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

  • Change of therapy for prostate cancer planned during the study intervention.
  • History or symptoms of urinary retention (not an exclusion if this occurred before prostatectomy), extra-urethral incontinence, overflow incontinence.
  • Active urinary tract infection (UTI) at screening or history of recurrent urinary tract infections (>= 4 UTIs within the 12 months prior to the study treatment initiation).
  • History of complete denervation of the pelvic floor.
  • Severe obesity (body mass index [BMI] >35).
  • Pelvic pain/painful bladder syndrome.
  • Metal implant in the abdominal or pelvic area.
  • History of chronic cough with ongoing symptoms
  • An implanted cardiac device, history of untreated cardiac arrhythmia, or history of other heart problems.
  • History of epilepsy.
  • History of underlying neurologic/neuromuscular disorder that could contribute to urinary incontinence.
  • Change in medications prescribed for urinary incontinence within 2 weeks prior to the study treatment initiation.
  • Uncontrolled intercurrent illness evaluated by medical history and physical examination or social situations that would limit compliance with study requirements.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:1/Elidah Device

Elidah device application.

The Elidah device is a modified version of the FDA approved ELITONE device cleared for use in the treatment of female stress urinary incontinence. For the current study, only minor modifications have been implemented with respect to the shape of the electrode component, providing a contour better suited to fit the male anatomy.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
To describe the efficacy of the Elidah device treatment on male urinary incontinence
時間枠:Baseline and within 2 weeks after completing treatment

Percent decrease in 24-hour pad weight after treatment with the Elidah device.

Baseline and within 2 weeks after completing treatment

二次結果の測定

結果測定
メジャーの説明
時間枠
To assess the safety of the Elidah device in men with urinary incontinence
時間枠:3 week visit and end of treatment visit

Frequency of adverse events among treated participants and reporting the results, by maximum grade of event and type of toxicity noted.

3 week visit and end of treatment visit
To assess alternative measures of efficacy of Elidah device on male urinary incontinence and bother
時間枠:Baseline and at end of treatment visit

Evaluated by the number of pads and number of leaks before and after treatment. The mean of the percent reduction in the number of pads used per day following treatment will be computed along with 95% confidence intervals.

Baseline and at end of treatment visit
To assess participant-reported outcomes of Elidah device use for male urinary incontinence
時間枠:Baseline and at end of treatment visit

The proportion of participants for which the I-QoL score improves by 2.5 points or more following six weeks of Elidah device use will be estimated. 95% confidence intervals for this proportion will be constructed.

Baseline and at end of treatment visit
To assess treatment compliance with the Elidah device
時間枠:3 week visit and end of treatment visit

A test of binomial proportions will be performed to assess whether the treatment noncompliance rate is above the unacceptability threshold.

3 week visit and end of treatment visit

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Deborah E Citrin, M.D.、National Cancer Institute (NCI)

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年2月15日

一次修了 (推定)

2027年12月1日

研究の完了 (推定)

2028年3月1日

試験登録日

最初に提出

2023年12月1日

QC基準を満たした最初の提出物

2023年12月1日

最初の投稿 (実際)

2023年12月8日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月10日

QC基準を満たした最後の更新が送信されました

2026年11月7日

最終確認日

2026年11月6日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

All IPD recorded in the medical record will be shared with intramural investigators upon request.

IPD 共有時間枠

Clinical data available during the study and indefinitely.

IPD 共有アクセス基準

Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する